A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis

NCT ID: NCT01821248

Last Updated: 2019-02-21

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-07-23
• Study Completion Date: 2019-02-28

Brief Summary

To evaluate the efficacy and the safety of preoperative chemotherapy with Gemcitabine/ Cisplatin /S-1 for biliary tract cancers with lymph node metastasis by FDG-PET.

Detailed Description

Biliary tract cancer is one of the most lethal malignancies worldwide, with surgery representing the only potentially curative treatment for this disease. However, many patients are diagnosed as far advanced stage, which is too late for curative resection, and even if surgery can be performed, the likelihood of relapse is very high. Lymph node metastasis is the most powerful prognostic factor in biliary tract cancer, which makes accurate preoperative assessment of lymph node metastasis important for indication of resection. However, the diagnostic accuracy, sensitivity, and specificity of conventional imaging techniques, including computed tomography (CT) and magnetic resonance imaging (MRI), seem to be insufficient for accurate detection of lymph node metastasis. Previously, the investigators reported FDG-PET is useful for prediction of lymph node metastasis.

On the other hand, gemcitabine has been widely used to treat the patients with unresectable or recurrent biliary tract cancer. In the Advanced Biliary tract Cancer (ABC)-02 study, the first prospective multicenter phase III study in this field, the combination of gemcitabine/cisplatin was compared with gemcitabine monotherapy and found that the combination regimen significantly prolonged Median Survival Time (MST) (from 8.1 to 11.7 months; P < 0.001). Gemcitabine/cisplatin combination therapy is now considered to be the standard regimen for advanced biliary tract cancer. S-1 is an oral fluoropyrimidine prodrug that has confirmed efficacy against various solid tumors, both alone and in combination with other cytotoxic drugs. S-1 monotherapy has yielded good results against advanced biliary tract cancer and gemcitabine/S-1 combination therapy has yielded promising results with acceptable toxicity levels for patients with advanced biliary tract cancer.

Furthermore, the investigators reported the safety and efficacy of adding S-1 to gemcitabine/cisplatin combination regimen (GCS) for advanced biliary tract cancer.

In this study, the investigators evaluate the efficacy and the safety of preoperative chemotherapy with Gemcitabine/ Cisplatin /S-1 for biliary tract cancers with lymph node metastasis by FDG-PET

Conditions

Biliary Tract Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Gemcitabine, Cisplatin, S-1

1000mg/m2/day1, 25mg/m2/day1, 100mg/body/day1-7

Group Type: EXPERIMENTAL

Gemcitabine, Cisplatin, S-1

Intervention Type: DRUG

Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery

GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7

Interventions

Gemcitabine, Cisplatin, S-1

Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery

GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7

Intervention Type: DRUG

Other Intervention Names

Gemcitabine；gemzer; Cisplatin；Cispulan; S-1；TS-1

Eligibility Criteria

Inclusion Criteria

1. Patients with radiologically proven biliary tract cancer.

2. No extra-hepatic disease.

3. No prior therapy.

4. The function of the liver is kept as satisfied after hepatectomy.

5. No chronic liver damage.

6. Patients of age over 20 years.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.

8. Sufficient organ function (neutrophil count >=1,500/mm3 and platelet count >=100,000/mm3, Hemoglobin >=9.0g/dL, Aspartate transaminase (AST)/alanine aminotransferase (ALT) <=150 IU/L, total bilirubin <=1.5 mg/dL , creatinine <=1.2 mg/dL , creatinine clearance >=60 mL/min) 9.Patients obtained written informed consent.

Exclusion Criteria

1. Massive abdominal effusion requiring treatment.

2. Active concomitant malignancy.

3. The case suspected of infection.

4. Patients with water solubility diarrhea.

5. Mental disease or psychotic manifestation.

6. Under continuous steroid therapy.

7. Patients with acute myocardial infarction.

8. Patients with severe complications.

9. Pregnancy or the desire to preserve fecundity.

10. Serious drug hypersensitivity or a history of drug allergy.

11. Any patients judged by the investigator to be unfit to participate in the study.

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kansai Hepatobiliary Oncology Group

NETWORK

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Etsuro Hatano, MD, PhD

Role: STUDY_DIRECTOR

Kyoto University

Locations

Kyoto University Hospital

Kyoto, , Japan

Countries

Japan

Other Identifiers

UMIN000009831

Identifier Type: REGISTRY

Identifier Source: secondary_id

KHBO1201

Identifier Type: -

Identifier Source: org_study_id